Sign Up to like & get
recommendations!
1
Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.3544
Abstract: 3544Background: FOLFOXIRI/bev is a highly efficacious first line regimen in MCRC. Despite higher rates of neutropenia, diarrhea and stomatitis, FOLFOXIRI/bev is tolerable and feasible in MCRC patients. To date nothing is known about the impact…
read more here.
Keywords:
folfox bev;
mcrc;
analysis;
bev ... See more keywords